Pharmaceutical Gelatin Market Research Reportβ€”Global Forecast till 2030

Pharmaceutical Gelatin Market: by Source (Porcine, Bovine Skin, Animal Bones, and Others), by Function (Stabilizer, Thickener, Gelling Agent, and Others), by Application (Hard Capsules, Soft Capsules, Micro-encapsulation, Coating for Tablets, Absorbable Hemostat, and Others), by Type (Type A, Type B), and by Region (North America, Europe, Asia-Pacific, and Rest of the World)β€”Forecast to 2030

ID: MRFR/HC/9411-HCR | August 2022 | Region: Global | 120 Pages         

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Regional Impact

5.3.4. Opportunity and Threat Analysis

6. GLOBAL PHARMACEUTICAL GELATIN MARKET, BY SOURCE

6.1. Overview

6.2. Porcine

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

6.3. Bovine Skin

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

6.4. Animal Bones

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

6.5. Others

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

7. GLOBAL PHARMACEUTICAL GELATIN MARKET, BY FUNCTION

7.1. Overview

7.2. Stabilizer

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

7.3. Thickener

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

7.4. Gelling Agent

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

7.5. Others

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

8. GLOBAL PHARMACEUTICAL GELATIN MARKET, BY APPLICATION

8.1. Overview

8.2. Hard Capsules

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

8.3. Soft Capsules

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

8.4. Micro-encapsulation

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

8.5. Coating for Tablets

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

8.6. Absorbable Hemostat

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

8.7. Others

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

9. GLOBAL PHARMACEUTICAL GELATIN MARKET, BY TYPE

9.1. Overview

9.2. Type A

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

9.3. Type B

Market Estimates & Forecast, by Region, 2018–2030

Market Estimates & Forecast, by Country, 2018–2030

10. GLOBAL PHARMACEUTICAL GELATIN MARKET, BY REGION

10.1. Overview

10.2. North America

10.2.1. US

10.2.2. Canada

10.3. Europe

10.3.1. Germany

10.3.2. France

10.3.3. Italy

10.3.4. Spain

10.3.5. UK

10.3.6. Rest of Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Rest of the World

10.5.1. Middle East

10.5.2. Africa

10.5.3. Latin America

11. COMPANY LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Global Pharmaceutical Gelatin Market

11.5. Competitive Benchmarking

11.6. Leading Players in terms of Number of Developments in the Global Pharmaceutical Gelatin Market

11.7. Key Developments and Growth Strategies

11.7.1. New Product Launch/Service Deployment

11.7.2. Merger & Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial

11.8.1. Sales & Operating Income, 2021

11.8.2. Major Players R&D Expenditure, 2021

12. COMPANY PROFILES

12.1. Darling Ingredients Inc.

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Products Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Nitta Gelatin Inc.

12.2.1. Company Overview

12.2.2. Financial Overview

12.2.3. Products Offered

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Tessenderlo Group

12.3.1. Company Overview

12.3.2. Financial Overview

12.3.3. Products Offered

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Gelita AG

12.4.1. Company Overview

12.4.2. Financial Overview

12.4.3. Products Offered

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Weishardt International

12.5.1. Company Overview

12.5.2. Financial Overview

12.5.3. Products Offered

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Trobas Gelatine B.V.

12.6.1. Company Overview

12.6.2. Financial Overview

12.6.3. Products Offered

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Lonza Group AG

12.7.1. Company Overview

12.7.2. Financial Overview

12.7.3. Products Offered

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Lapi Gelatine S.p.A

12.8.1. Company Overview

12.8.2. Financial Overview

12.8.3. Products Offered

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Italgelatine S.p.A

12.9.1. Company Overview

12.9.2. Financial Overview

12.9.3. Products Offered

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Xiamen Gelken Gelatin Co. Ltd.

12.10.1. Company Overview

12.10.2. Financial Overview

12.10.3. Products Offered

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. Gelco International

12.11.1. Company Overview

12.11.2. Financial Overview

12.11.3. Products Offered

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. Aspire Pharmaceuticals

12.12.1. Company Overview

12.12.2. Financial Overview

12.12.3. Products Offered

12.12.4. Key Developments

12.12.5. SWOT Analysis

12.12.6. Key Strategies

12.13. India Gelatine & Chemicals Ltd.

12.13.1. Company Overview

12.13.2. Financial Overview

12.13.3. Products Offered

12.13.4. Key Developments

12.13.5. SWOT Analysis

12.13.6. Key Strategies

12.14. Gelnex Industria E Comercio Ltda

12.14.1. Company Overview

12.14.2. Financial Overview

12.14.3. Products Offered

12.14.4. Key Developments

12.14.5. SWOT Analysis

12.14.6. Key Strategies

12.15. Henan Boom Gelatin Co. Ltd

12.15.1. Company Overview

12.15.2. Financial Overview

12.15.3. Products Offered

12.15.4. Key Developments

12.15.5. SWOT Analysis

12.15.6. Key Strategies

12.16. Baotou Dongbao Bio-Tech Co. Ltd

12.16.1. Company Overview

12.16.2. Financial Overview

12.16.3. Products Offered

12.16.4. Key Developments

12.16.5. SWOT Analysis

12.16.6. Key Strategies

12.17. Norland Products Inc.

12.17.1. Company Overview

12.17.2. Financial Overview

12.17.3. Products Offered

12.17.4. Key Developments

12.17.5. SWOT Analysis

12.17.6. Key Strategies

12.18. Geltech Co. Ltd

12.18.1. Company Overview

12.18.2. Financial Overview

12.18.3. Products Offered

12.18.4. Key Developments

12.18.5. SWOT Analysis

12.18.6. Key Strategies

12.19. Geliko LLC

12.19.1. Company Overview

12.19.2. Financial Overview

12.19.3. Products Offered

12.19.4. Key Developments

12.19.5. SWOT Analysis

12.19.6. Key Strategies

12.20. Kenney & Ross Limited

12.20.1. Company Overview

12.20.2. Financial Overview

12.20.3. Products Offered

12.20.4. Key Developments

12.20.5. SWOT Analysis

12.20.6. Key Strategies

13. APPENDIX

13.1. References

13.2. Related Reports

 

LIST OF TABLES

TABLE 1 GLOBAL PHARMACEUTICAL GELATIN MARKET SYNOPSIS, 2018–2030

TABLE 2 GLOBAL PHARMACEUTICAL GELATIN MARKET ESTIMATES & FORECAST, 2018–2030 (USD MILLION)

TABLE 3 GLOBAL PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 7 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 8 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 9 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 10 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 11 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 12 US: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 13 US: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 14 US: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 15 US: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 16 CANADA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 17 CANADA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 18 CANADA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 19 CANADA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 20 EUROPE: PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 21 EUROPE: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 22 EUROPE: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 23 EUROPE: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 24 EUROPE: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 25 GERMANY: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 26 GERMANY: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 27 GERMANY: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 28 GERMANY: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 29 FRANCE: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 30 FRANCE: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 31 FRANCE: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 32 FRANCE: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 33 ITALY: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 34 ITALY: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 35 ITALY: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 36 ITALY: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 37 SPAIN: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 38 SPAIN: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 39 SPAIN: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 40 SPAIN: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 41 UK: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 42 UK: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 43 UK: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 44 UK: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 45 REST OF EUROPE: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 46 REST OF EUROPE: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 47 REST OF EUROPE: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 48 REST OF EUROPE: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 49 ASIA-PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 54 JAPAN: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 55 JAPAN: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 56 JAPAN: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 57 JAPAN: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 58 CHINA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 59 CHINA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 60 CHINA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 61 CHINA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 62 INDIA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 63 INDIA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 64 INDIA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 65 INDIA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 66 AUSTRALIA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 67 AUSTRALIA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 68 AUSTRALIA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 69 AUSTRALIA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 70 SOUTH KOREA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 71 SOUTH KOREA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 72 SOUTH KOREA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 73 SOUTH KOREA: PHARMACEUTICAL GELATIN MARKET, BY TYPE 2018–2030 (USD MILLION)

TABLE 74 REST OF ASIA-PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 75 REST OF ASIA-PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 76 REST OF ASIA-PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 77 REST OF ASIA-PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 78 REST OF THE WORLD: PHARMACEUTICAL GELATIN MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 79 REST OF THE WORLD: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 80 REST OF THE WORLD: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 81 REST OF THE WORLD: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 82 REST OF THE WORLD: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 83 MIDDLE EAST: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 84 MIDDLE EAST: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 85 MIDDLE EAST: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 86 MIDDLE EAST: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 87 AFRICA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 88 AFRICA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 89 AFRICA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 90 AFRICA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 91 LATIN AMERICA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 92 LATIN AMERICA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2018–2030 (USD MILLION)

TABLE 93 LATIN AMERICA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 94 LATIN AMERICA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2018–2030 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PHARMACEUTICAL GELATIN MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PHARMACEUTICAL GELATIN MARKET

FIGURE 4 GLOBAL PHARMACEUTICAL GELATIN MARKET SHARE (%), BY SOURCE, 2021

FIGURE 5 GLOBAL PHARMACEUTICAL GELATIN MARKET SHARE (%), BY FUNCTION, 2021

FIGURE 6 GLOBAL PHARMACEUTICAL GELATIN MARKET SHARE (%), BY APPLICATION, 2021

FIGURE 7 GLOBAL PHARMACEUTICAL GELATIN MARKET SHARE (%), BY TYPE, 2021

FIGURE 8 GLOBAL PHARMACEUTICAL GELATIN MARKET SHARE (%), BY REGION, 2021

FIGURE 9 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET SHARE (%), BY REGION, 2021

FIGURE 10 EUROPE: PHARMACEUTICAL GELATIN MARKET SHARE (%), BY REGION, 2021

FIGURE 11 ASIA-PACIFIC: PHARMACEUTICAL GELATIN MARKET SHARE (%), BY REGION, 2021

FIGURE 12 REST OF THE WORLD: PHARMACEUTICAL GELATIN MARKET SHARE (%), BY REGION, 2021

FIGURE 13 GLOBAL PHARMACEUTICAL GELATIN MARKET: COMPANY SHARE ANALYSIS (%), 2021

FIGURE 14 DARLING INGREDIENTS INC.: FINANCIAL OVERVIEW

FIGURE 15 DARLING INGREDIENTS INC.: SWOT ANALYSIS

FIGURE 16 NITTA GELATIN INC.: FINANCIAL OVERVIEW

FIGURE 17 NITTA GELATIN INC.: SWOT ANALYSIS

FIGURE 18 TESSENDERLO GROUP: FINANCIAL OVERVIEW

FIGURE 19 TESSENDERLO GROUP: SWOT ANALYSIS

FIGURE 20 GELITA AG: FINANCIAL OVERVIEW

FIGURE 21 GELITA AG: SWOT ANALYSIS

FIGURE 22 WEISHARDT INTERNATIONAL: FINANCIAL OVERVIEW

FIGURE 23 WEISHARDT INTERNATIONAL: SWOT ANALYSIS

FIGURE 24 TROBAS GELATINE B.V.: FINANCIAL OVERVIEW

FIGURE 25 TROBAS GELATINE B.V.: SWOT ANALYSIS

FIGURE 26 LONZA GROUP AG: FINANCIAL OVERVIEW

FIGURE 27 LONZA GROUP AG: SWOT ANALYSIS

FIGURE 28 LAPI GELATINE S.P.A: FINANCIAL OVERVIEW

FIGURE 29 LAPI GELATINE S.P.A: SWOT ANALYSIS

FIGURE 30 ITALGELATINE S.P.A: FINANCIAL OVERVIEW

FIGURE 31 ITALGELATINE S.P.A: SWOT ANALYSIS

FIGURE 32 XIAMEN GELKEN GELATIN CO. LTD.: FINANCIAL OVERVIEW

FIGURE 33 XIAMEN GELKEN GELATIN CO. LTD.: SWOT ANALYSIS

FIGURE 34 GELCO INTERNATIONAL: FINANCIAL OVERVIEW

FIGURE 35 GELCO INTERNATIONAL: SWOT ANALYSIS

FIGURE 36 ASPIRE PHARMACEUTICALS: FINANCIAL OVERVIEW

FIGURE 37 ASPIRE PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 38 INDIA GELATINE & CHEMICALS LTD.: FINANCIAL OVERVIEW

FIGURE 39 INDIA GELATINE & CHEMICALS LTD.: SWOT ANALYSIS

FIGURE 40 GELNEX INDUSTRIA E COMERCIO LTDA: FINANCIAL OVERVIEW

FIGURE 41 GELNEX INDUSTRIA E COMERCIO LTDA: SWOT ANALYSIS

FIGURE 42 HENAN BOOM GELATIN CO. LTD: FINANCIAL OVERVIEW

FIGURE 43 HENAN BOOM GELATIN CO. LTD: SWOT ANALYSIS

FIGURE 44 BAOTOU DONGBAO BIO-TECH CO. LTD: FINANCIAL OVERVIEW

FIGURE 45 BAOTOU DONGBAO BIO-TECH CO. LTD: SWOT ANALYSIS

FIGURE 46 NORLAND PRODUCTS INC.: FINANCIAL OVERVIEW

FIGURE 47 NORLAND PRODUCTS INC.: SWOT ANALYSIS

FIGURE 48 GELTECH CO. LTD: FINANCIAL OVERVIEW

FIGURE 49 GELTECH CO. LTD: SWOT ANALYSIS

FIGURE 50 GELIKO LLC: FINANCIAL OVERVIEW

FIGURE 51 GELIKO LLC: SWOT ANALYSIS

FIGURE 52 KENNEY & ROSS LIMITED: FINANCIAL OVERVIEW

FIGURE 53 KENNEY & ROSS LIMITED: SWOT ANALYSIS

Pharmaceutical Gelatin Market Overview


The pharmaceutical gelatin market is expected to cross USD 1,595.8 million by 2030 at a CAGR of 6.4%. Pharmaceutical gelatin is a colorless, water soluble, thermo-reversible, biocompatible, translucent, and a sensitive element that has a high molecular weight. It is derived from animal skin, white connective tissues, and bones of animals by partial hydrolysis of collagen. Gelatin is widely used as an excipient in the production of hard capsules and soft gels. In addition, it is also used as a binder in tablets, utilized as blood plasma substitutes, and others.  Various manufacturers provide pharmaceutical gelatin across the world such as Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Gelita AG (Germany), and others. For instance, Darling Ingredients Inc. (US) provides pharmaceutical-grade gelatins such as X-Pure globally. The X-Pure range such as X-Pure Gelatin, X-Pure GelMA, and X-Pure GelDAT offers premium quality gelling and non-gelling gelatins sourced from porcine skin. It provides significant technical advantages for the development of biomedical applications.


The pharmaceutical gelatin market is expected to rise significantly in the forecast period, owing to the factors such as growing nutraceuticals & pharmaceutical companies across the world uses gelatin to manufacture drugs. In addition, rising applications of pharmaceutical gelatin for the production of hard & soft gel capsules, tablets and vaccine fuels the market growth. Moreover, rising prevalence of chronic diseases, advancements in technology, low manufacturing cost for making gelatin capsule shells, and increasing awareness about the consumption of nutrition rich food are boosting the market growth during the forecast period.


COVID-19 Analysis


The global pharmaceutical gelatin market is projected to witness significant growth in this pandemic period. With the onset of the COVID-19 pandemic, the increasing use of medications related to COVID-19 for the treatment is expected to have an impact on market growth. The demand for capsules and tablets has increased during COVID-19 pandemic for the treatment of COVID-19, pneumonia, and other infectious diseases. Moreover, pharmaceutical gelatin is often used in COVID-19 vaccines to keep the drug's ingredients stable and effective during the distribution procedure. According to the Our World in Data, 10.91 billion vaccines doses have been administered globally as of 13th March 2022, with 17.92 million vaccines doses being administered every day. Hence, rising number of administration of doses will increase demand for pharmaceutical gelatin to develop effective vaccines during the forecast period.


In terms of the supply-chain, transport, and logistics challenges have arisen as a result of the quarantine and lockdown measures imposed in several regions, making it difficult to obtain raw material for gelatin. Also, this has caused a supply-demand gap in some areas, resulting in a shortage of pharmaceutical gelatin. Hence, reducing imports and exports between borders may cause supply chain disruptions, resulting in a significant loss for raw material suppliers.


Pharmaceutical Gelatin Market Dynamics


Drivers


  • Rising demand of pharmaceutical gelatin

    • Pharmaceutical gelatin is a combination of protein & peptide made up from collagen that's been partially hydrolyzed. The collagen used to make gelatin comes from animal bones and skin trimmings. Pharmaceutical gelatin has demonstrated its versatility in applications for the pharmaceutical and medical uses. Pharmaceutical gelatin is used for the production of capsules, tablets, vaccines, wound dressings, hemostatic sponges, and blood volume substitutes in the pharmaceutical and medical devices industries. Moreover, pharmaceutical gelatin is a useful biomaterial in regenerative medicine as this mimic the extracellular matrix and promotes cell development. It also aids in the enhancement of cell viability. Hence, rising demand of pharmaceutical gelatin worldwide drives the growth of the pharmaceutical gelatin market.

    • Additionally, gelatin's unique functional characteristics, such as gelling, adhesion, coating, binding, and film-building are ideally suited for pharmaceutical applications. The gelatin coating on hard capsules, softgel capsules, and tablets suppresses the odour of the medicine while also making swallowing easier. Furthermore, it gives protection against environmental changes such as oxygen, moisture, and extends the shelf life of pharmaceutical medications. Therefore, the rising applications of pharmaceutical gelatin for new drug development is driving the pharmaceutical gelatin market growth.





  • Surge in use of gelatin among nutraceutical & pharmaceutical drug manufacturer


Market Restraints


  • Presence of substitute components

    • The increasing demand for plant-based alternatives such as hydroxypropyl methylcellulose (HPMC) and modified starch are used to manufacture vegetarian capsule shells. Moreover, the rising trend in veganism across the world hinders the consumption of animal-based products, hence restrain the pharmaceutical gelatin market



  • Stringent regulatory requirements for pharmaceutical gelatin


Market Opportunities


  • Rise in demand for pharmaceutical-grade gelatin in emerging countries

    • Emerging markets such as Asia-Pacific, the Middle East, Latin America, and Africa provide considerable prospects for the expansion of pharmaceutical gelatin market. Moreover, several raw gelatin and gelatin capsule manufacturers are taking steps to extend their company presence and production capacity in India, China, and other emerging countries is fueling the growth of the market. Hence, rising demand of pharmaceutical gelatin in emerging economies, availability of raw material and decreased labor prices are anticipated to provide significant growth opportunities for the global pharmaceutical gelatin market.



  • Pharmaceutical Gelatin Market Value Chain Analysis

    • An increasing number of patients are suffering from chronic diseases such as cardiovascular diseases, diabetes, cancer, arthritis, and others increases the demand for medications for the treatment. As a result, pharmaceutical gelatin is projected to gain more importance due to its broad-spectrum qualities such as excellent bioavailability, protect active pharmaceutical ingredients from contamination, and the potential for modified release that make it a highly effective excipient for pharmaceutical applications. The pharmaceutical gelatin market is predicted to grow in the next years, and it will be useful to make capsules, tablets, vaccines, emulsions, suppositories, and others in pharmaceutical industry. The value chain analysis for the global pharmaceutical gelatin market comprises four major components that start with the research and product development (R&D), followed by the manufacturing of the products, distribution & sales, and ends with post-sales monitoring.



  • Pharmaceutical Gelatin Market Segment Overview


By Source


  • Porcine

    • Pig skins or bones are the most important source of materials for pharmaceutical gelatin. The pig skin product is commonly used as a thickening, stabilizer, texturizer, and binder in capsules & tablets. Moreover, gelatin-based hemostats are primarily produced from porcine collagen (porcine skin) and come in the form of sponges, strips, powder, and nanofibers. Porcine based gelatin is one is the most commercially used gelatin worldwide, owing to its cheaper price & easier availability.



  • Bovine Skin

    • Bovine species include bison, yak, antelope, water buffalo, and cows. Pharmaceutical gelatin obtained from bovine skin is a colourless, transparent, flavourless, and brittle in nature. It is typically utilized as a jelling agent in pharmaceutical drugs and cosmetic industry. For instance, Merck KGaA (Germany) offers gelatin from bovine skin.



  • Animal Bones

    • Pharmaceutical gelatin is also derived from cow, pork, and fish bones. The bones of certain animals usually cows and pigs are boiled, dried, treated with a strong acid or base, and lastly filtered to remove the collagen. To synthesize pharmaceutical gelatin, the collagen is dried, pulverised into a powder, and sifted.



  • Others

    • Other sources for pharmaceutical gelatin include chicken, fish skins, and others.




By Function


  • Stabilizer

    • Pharmaceutical gelatin is used as a stabilizer in capsules, vaccines, and other dosage forms. In vaccines, purified pharmaceutical gelatin with minimal endotoxin level is utilized as a stabilizer. It enhances in the stability of lyophilized (freeze-dried) products, reduces the potential for side effects, and ensures patient safety.



  • Thickener

    • Pharmaceutical gelatin is used as a thickener in medicinal syrups, elixirs, and other liquid dosage forms. Moreover, pharmaceutical gelatin is utilized to improve the viscosity of the dosage form while keeping the other components unaltered. It is used as a thickener in antibiotic creams and lotions.



  • Gelling Agent

    • Gelling agents are the gel-forming agents when dispersed in a liquid phase as a homogeneous mixture develop a weakly cohesive internal structure. Pharmaceutical gelatin is used as a gelling agent in medications, drug & vitamin capsules, and in cosmetics products.



  • Others

    • Other functions of pharmaceutical gelatin include film forming, water-binding agent, foaming agent, thermo-reversible, and others.




By Application


  • Hard Capsules

    • Pharmaceutical gelatin is one of the most common and well-known material used to produce hard capsules. It has lower production costs, less manufacturing constraints, and ensures superior active pharmaceutical ingredient (API) dissolving rates. Moreover, hard capsules are an oral dose form for the supplementation of life-saving medications, minerals, vitamins, and other healthy elements. Hence, rising prevalence of chronic diseases will increase the demand of hard capsules, ultimately increases the pharmaceutical gelatin market segment growth.



  • Soft Capsules

    • Soft capsules (softgels) are hermetically sealed capsules that contain liquids or semisolid contents. They are easy to use, identify, and swallow due to their lack of friction. Moreover, soft capsules are patient-friendly dosage form due to the capability of being formulated appropriately for rapid or slow release and having a high degree of reproducibility.



  • Coating for Tablets

    • Tablet coating is the process where pharmaceutical gelatin is most preferred coating material applied to the surface of the tablet to improve taste, odor, color, and ease of swallowing by the patient. Moreover, it is also improved tablets stability. The pharmaceutical gelatin coating provides a low coefficient of friction to the tablet, increasing slipperiness and swallowability of tablets without adding stickiness or thickness agents. Moreover, growing adoption of tablet dosage form among the growing geriatric population, and the rising adoption of orphan drugs are supporting the growth of the pharmaceutical gelatin market segment.



  • Absorbable Hemostat

    • Purified porcine-derived pharmaceutical gelatin has excellent hemostatic properties due to its high fluid absorption and water swelling capacity, it is used by surgeons to minimize blood loss during surgery. Allowing it to concentrate serum proteins, aggregate red blood cells, promote platelet aggregation, and tamp the wound to prevent blood loss. In addition, absorbable gelatin sponge is used in chemotherapy to embolize arteries in the vicinity of a tumour in order to obstruct or slow blood flow. For instance, Spongostan Absorbable Haemostatic Gelatin Sponge, which is offered by Ethicon, Inc. (US).



  • Others

    • Other applications of pharmaceutical gelatin include in regenerative medicine, in femoral plugs as a plasticizer for a more elastic shape, in Vaccines, and others.




By Type


  • Type A

    • Pharmaceutical gelatin derived from pig skin is normally referred to as type A gelatin. it has a broad isoelectric range between pH 7-9, adjusted to an acidic pH which is below the isoelectric point.



  • Type B

    • Pharmaceutical gelatin derived from beef skin is normally referred to as type B gelatin. it has a narrower isoelectric range between pH 4.7-5.4, produced from an alkali-treated precursor.



  • Pharmaceutical Gelatin Market Regional Analysis


North America


  • Rise in chronic diseases and presence of key players in the region are driving the North American pharmaceutical gelatin market

    • North America holds the largest share in 2021 in pharmaceutical gelatin market, owing to the increasing prevalence of chronic diseases such as osteoarthritis, cancer, and others, and presence of major key players in the region. These players are involved in acquisitions, business expansions, and strategic collaborations. For instance, in January 2022, Darling Ingredients Inc. (US) collaborated with the Terasaki Institute for Biomedical Innovation (US), a California-based research institute focused on regenerative medicine. This collaboration will be helpful for development and translation of gelatin-based medicines into the clinics.




Europe


  • Rising use of pharmaceutical gelatin in regenerative medicine, and ample availability of raw materials is anticipated to drive the growth of the pharmaceutical gelatin market

    • Europe accounts for the second-largest market share due to the ample availability of raw materials such as porcine & bovine in the region. In addition, rising use of pharmaceutical gelatin in regenerative medicine for its cell-responsive characteristics and ability to transport a diverse range of biomolecules is also expected to boost the market growth in the region.




Asia-Pacific


  • The increasing prevalence of chronic diseases is fueling the Asia-Pacific pharmaceutical gelatin market

    • The Asia-Pacific pharmaceutical gelatin market is projected to be the fastest-growing regional market. The increasing prevalence of chronic diseases such as cardiovascular disorders, diabetes, osteoarthritis, and cancer are demands new drug development for the treatment. Ultimately, increases the demand of pharmaceutical gelatin as an excipient for various pharmaceutical dosage forms such as capsules, tablets, suspensions, emulsions, injections, and others. Moreover, rising number of contract research & manufacturing companies, and lower labor & capital costs for the manufacturing of pharmaceutical gelatin is also driving the growth of the market in the Asia Pacific region.




Rest of the World:


  • The rest of the world is comprised of the Middle East, Africa, and Latin America. The pharmaceutical gelatin market in the rest of the world is driven by rising government initiatives for improving the healthcare sector and increasing R&D in pharmaceutical and medical devices industry. Furthermore, rising applications of pharmaceutical gelatin for anticancer drugs delivery, gene delivery, pulmonary drug delivery, ocular drug delivery, protein delivery, and others in the region also contributing to the growth of the pharmaceutical gelatin market.


Pharmaceutical Gelatin Market Competitive Landscape


  • The pharmaceutical gelatin market is profitable, both for existing players as well as new entrants. Our analysis revealed that market players have adopted different strategies such as joint ventures, contractual agreements, new product launches, and partnering with other players to expand their global footprint. For instance, In December 2020, Gelita AG (Germany) acquired 65% shares of the SelJel (Turkey) to strengthen its position as the industry's global leader. This acquisition will also meet the increasing demand for gelatin, and in particular for halal bovine gelatin. The companies are investing in R&D activities to expand their product portfolio, which further driving the pharmaceutical gelatin market.


List of Key Companies Covered in this Report:   


  • Darling Ingredients Inc. (US)

  • Nitta Gelatin Inc. (Japan)

  • Tessenderlo Group (Belgium)

  • Gelita AG (Germany)

  • Weishardt International (France)

  • Trobas Gelatine B.V. (Netherlands)

  • Lonza Group AG (Switzerland)

  • Lapi Gelatine S.p.A (Italy)

  • Italgelatine S.p.A (Italy)

  • Xiamen Gelken Gelatin Co. Ltd. (China)

  • Gelco International (Brazil)

  • Aspire Pharmaceuticals (US)

  • India Gelatine & Chemicals Ltd. (India)

  • Gelnex Industria E Comercio Ltda (Brazil)

  • Henan Boom Gelatin Co. Ltd (China)

  • Baotou Dongbao Bio-Tech Co. Ltd (China)

  • Norland Products Inc. (US)

  • Geltech Co. Ltd (South Korea)

  • Geliko LLC (US)

  • Kenney & Ross Limited (Canada)


Recent Developments


  • In December 2021, Lapi Gelatine S.p.A (Italy) acquired Junca Gelatines (Spain). This acquisition will be expanding its presence in the industrial gelatin sector for pharmaceutical uses.

  • In May 2021, Darling Ingredients Inc. (US) launched X-Pure GelDAT – Gelatin Desaminotyrosine. This new product provides purity and consistency on a high level, which is critical for the successful development of biomedical products employed in the human body.


Pharmaceutical Gelatin Market Report Overview


  • The study covers the existing short-term and long-term market effects, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.


Scope of the Report & Segmentation

By Source


  • Porcine

  • Bovine Skin

  • Animal Bones

  • Others


By Function


  • Stabilizer

  • Thickener

  • Gelling Agent

  • Others


By Application


  • Hard Capsules

  • Soft Capsules

  • Micro-encapsulation

  • Coating for Tablets

  • Absorbable Hemostat

  • Others


By Type


  • Type A

  • Type B


By Region


  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America





Report Scope:
Report Attribute/Metric Details
  Market Size   2030: USD 1,595.8 Million
  CAGR   6.4%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2018-2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Source, Function, Application, Type
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   β€’ Darling Ingredients Inc. (US) β€’ Nitta Gelatin Inc. (Japan) β€’ Tessenderlo Group (Belgium) β€’ Gelita AG (Germany) β€’ Weishardt International (France) β€’ Trobas Gelatine B.V. (Netherlands) β€’ Lonza Group AG (Switzerland) β€’ Lapi Gelatine S.p.A (Italy) β€’ Italgelatine S.p.A (Italy) β€’ Xiamen Gelken Gelatin Co. Ltd. (China) β€’ Gelco International (Brazil) β€’ Aspire Pharmaceuticals (US) β€’ India Gelatine & Chemicals Ltd. (India) β€’ Gelnex Industria E Comercio Ltda (Brazil) β€’ Henan Boom Gelatin Co. Ltd (China) β€’ Baotou Dongbao Bio-Tech Co. Ltd (China) β€’ Norland Products Inc. (US) β€’ Geltech Co. Ltd (South Korea) β€’ Geliko LLC (US) β€’ Kenney & Ross Limited (Canada)
  Key Market Opportunities   β€’ Rise in demand for pharmaceutical-grade gelatin in emerging countries
  Key Market Drivers   β€’ Rising demand of pharmaceutical gelatin β€’ Surge in use of gelatin among nutraceutical & pharmaceutical drug manufacturer


Speak to Analyst Ask for Customization